Therefore, we asked whether the central domain of Tab2 was also able to interact with other receptors, specifically with AR that plays a role in the response/resistance of prostate cancer cells to anti-androgenic drugs, in analogy to anti-estrogens in breast cancer cells. The gene discussed is AR; the disease is prostate carcinoma.